{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:38:49Z","timestamp":1791851929846,"version":"4.3.4"},"reference-count":20,"publisher":"Baskent University","issue":"Suppl 2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Clin Transplant"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.6002\/ect.iahncongress.25","type":"journal-article","created":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T04:26:17Z","timestamp":1690431977000},"page":"105-108","source":"Crossref","is-referenced-by-count":19,"title":["A Story of Serendipities: From Phlorizin to Gliflozins"],"prefix":"10.6002","volume":"21","author":[{"given":"\u00d6zant","family":"Helvac\u0131","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bur\u00e7ak","family":"Helvac\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4021","reference":[{"key":"ref0","unstructured":"References"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"1. Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia. 2022;65(12):1925-1966. doi:10.1007\/s00125-022-05787-2","DOI":"10.1007\/s00125-022-05787-2"},{"key":"ref2","unstructured":"2. Ahmed AM. History of diabetes mellitus. Saudi Med J. 2002;23(4):373-378."},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"3. Rost\u00e8ne W, De Meyts P. Insulin: a 100-year-old discovery with a fascinating history. Endocr Rev. 2021;42(5):503-527. doi:10.1210\/endrev\/bnab020","DOI":"10.1210\/endrev\/bnab020"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"4. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2022;102(5S):S1-S127. doi:10.1016\/j.kint.2022.06.008","DOI":"10.1016\/j.kint.2022.06.008"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"5. J\u00f6rgens V. The roots of SGLT inhibition: Laurent-Guillaume de Koninck, Jean Servais Stas and Freiherr Josef von Mering. Acta Diabetol. 2019;56(1):29-31. doi:10.1007\/s00592-018-1206-z","DOI":"10.1007\/s00592-018-1206-z"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"6. Desborough MJR, Keeling DM. The aspirin story - from willow to wonder drug. Br J Haematol. 2017;177(5):674-683. doi:10.1111\/bjh.14520","DOI":"10.1111\/bjh.14520"},{"issue":"1","key":"ref7","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/jlac.18350150105","article-title":"\u00dcber das Phloridzin (Phlorrhizin)","volume":"15","author":"De Koninck","year":"1835","unstructured":"7. De Koninck LG. \u00dcber das Phloridzin (Phlorrhizin). Annalen der Pharmacie. 1835;15(1):75-77.","journal-title":"Annalen der Pharmacie"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"8. Xiang L, Wang M, Jiang W, et al. Key indicators for renewal and reconstruction of perennial trees soil: Microorganisms and phloridzin. Ecotoxicol Environ Saf. 2021;225:112723. doi:10.1016\/j.ecoenv.2021.112723","DOI":"10.1016\/j.ecoenv.2021.112723"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"9. Joseph von Mering (1849-1908). Nature. 1949;164:1076. doi:10.1038\/1641076d0","DOI":"10.1038\/1641076d0"},{"key":"ref10","unstructured":"10. Diamandopoulos A, Bacharaki D, Vlachakos D. Dioscurides' observations on the diuretic properties of the malus (apple) species and its explanation with the phlorizin inhibitor of SGLT1 and SGLT2. Nefrol Dializ Polska. 2017;21(2)."},{"key":"ref11","unstructured":"11. Von Mering J. \u00dcber k\u00fcnstlichen diabetes. Centralblatt f\u00fcr die medizinische Wissenschaft. 1886;22:31."},{"key":"ref12","unstructured":"12. Von Mering J. \u00dcber Diabetes mellitus. Verhandlungen des VI Congresses f\u00fcr Innere Medizin in Wiesbaden. Bergmann; 1887:349-358."},{"key":"ref13","unstructured":"13. Minkowski O. Weitere Mittheilungen \u00fcber den diabetes mellitus nach Exstirpation des Pankreas. Berliner Klin Wochenschr. 1892;29:90-93."},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"14. Hamilton KL. Robert K. Crane-Na(+)-glucose cotransporter to cure? Front Physiol. 2013;4:53. doi:10.3389\/fphys.2013.00053","DOI":"10.3389\/fphys.2013.00053"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"15. Oku A, Ueta K, Arakawa K, et al. T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes. 1999;48(9):1794-1800. doi:10.2337\/diabetes.48.9.1794","DOI":"10.2337\/diabetes.48.9.1794"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"16. Meng W, Ellsworth BA, Nirschl AA, et al. Discovery of dapagliflozin: A potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem. 2008;51(5):1145-1149. doi:10.1021\/jm701272q","DOI":"10.1021\/jm701272q"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"17. Misbin RI. Lessons from the Avandia controversy: a new paradigm for the development of drugs to treat type 2 diabetes. Diabetes Care. 2007;30(12):3141-3144. doi:10.2337\/dc07-1908","DOI":"10.2337\/dc07-1908"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"18. Zinman B, Wanner C, Lachin JM, et al; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128. doi:10.1056\/NEJMoa1504720","DOI":"10.1056\/NEJMoa1504720"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"19. Braunwald E. Gliflozins in the management of cardiovascular disease. N Engl J Med. 2022;386(21):2024-2034. doi:10.1056\/NEJMra2115011","DOI":"10.1056\/NEJMra2115011"}],"container-title":["Experimental and Clinical Transplantation"],"original-title":[],"deposited":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T07:18:49Z","timestamp":1690442329000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.ectrx.org\/detail\/supplement\/2023\/21\/6\/2\/105\/0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":20,"journal-issue":{"issue":"Suppl 2","published-print":{"date-parts":[[2023,6]]}},"URL":"https:\/\/doi.org\/10.6002\/ect.iahncongress.25","relation":{},"ISSN":["1304-0855","2146-8427"],"issn-type":[{"value":"1304-0855","type":"print"},{"value":"2146-8427","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6]]}}}